Atopic Dermatitis, Atopic Dermatitis Eczema
Conditions
Brief summary
This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (14 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)
Detailed description
There is a screening period of about 2 weeks before the start of the test product. The subjects who meet the conditions of this test are randomly assigned according to the ratio of 1:1, and take the lactic acid bacteria NTU 101 or Placebo in the test group for a total of 12 weeks of treatment. Once, after the treatment, the test physician evaluated the safety and efficacy of the subjects taking the test group lactobacillus NTU 101 or Placebo. After the end of the treatment period, all subjects underwent a 2-week discontinuation follow-up period. This study will track subjects before and after taking samples, SCORing Atopic Dermatitis (Screen-Visit 4), Children's Dermatology Life Quality Index (Visit 1-Visit4), Patient-Oriented Eczema Measure (Visit 1-Visit4), to evaluate subjects Severity of illness. The subjects received the following tests before and after taking the samples: a full set of blood tests, leukocyte differential counts, serum biochemical tests (BUN, Creatinine, GOT, GPT), and collection of peripheral blood mononuclear cells and stool samples for analysis of the subjects immune function and gastrointestinal microbiota.
Interventions
DIETARY_SUPPLEMENTLactic acid bacteria NTU 101
One NTU 101 Lactic Acid Bacteria Vegetable Capsule a day for a total of 12 weeks. Product ingredients: microcrystalline cellulose, corn starch, NTU 101 Lactobacillus paracasei subsp. paracasei NTU 101 (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), purified water, titanium dioxide, gellan gum.
DIETARY_SUPPLEMENTPlacebo
Maltodextrin was used as a placebo
Sponsors
SunWay Biotech Co., LTD.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Masking description
With the random assignment system of Taipei Medical University, 6 Blocks, double-blind
Intervention model description
Test group: NTU 101 Lactobacillus Vegetable Capsules Product ingredients: microcrystalline cellulose, corn starch, NTU 101 lactic acid bacteria powder (1.8 x 10\^10 CFU); capsule shell composition: HPMC (hydroxypropyl methylcellulose), pure water, titanium dioxide, gellan gum.
Eligibility
Sex/Gender
ALL
Age
6 Years to 12 Years
Healthy volunteers
No
Inclusion criteria
\- According to the diagnostic criteria of Hanifin & Rajka atopic dermatitis, patients with clinical diagnosis of atopic dermatitis were screened and those who met the following conditions: 1. Age: Children over 6 years old and under 12 years old 2. Patients with moderate atopic dermatitis: SCORAD index 25 - 49.9 (moderate). 3. Atopic dermatitis diagnosed over 6 months
Exclusion criteria
1. Immunodeficiency: Congenital immunodeficiency: According to the classification principle of Current classification and status of primary immunodeficiency diseases in Taiwan, it is divided into (1) cellular/T-cell immunodeficiency (2) humoral immunodeficiency (Humoral/B- (3) Complement deficiency (4) Phagocyte deficiency. 2. Human immunodeficiency virus (Human Immunodeficiency Virus, HIV) infection (Inquired from medical records). 3. Other diseases that affect immune function, including kidney disease, diabetes, liver cirrhosis and chronic liver disease, asplenia. 4. Short Bowel Syndrome (Short Bowel Syndrome). 5. Patients with malignant tumors. 6. Patients with central venous catheters. 7. Secondary bacterial infection. 8. Received immunosuppressive and biological agents in the past 3 months (eg: dupilumab, Janus kinase (JAK) inhibitors, Janus kinase inhibitors). 9. Received oral or injectable steroids, antibiotics, and light therapy in the past 1 month. 10. Continuously (3 days or more) take Chinese herbal medicine, probiotic supplements or other fermented foods, such as yogurt, yogurt, and Yakult. 11. Abnormal liver or kidney function (1.5 times higher than normal). 12. Other skin diseases or other systemic diseases. 13. Participated in other clinical trials in the past 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SCORing Atopic Dermatitis (SCORAD) Improvement Total Score | 12 weeks | Compared with the placebo group, after taking probiotics or placebo for 4, 8, and 12 weeks, the atopic dermatitis severity score SCORAD in the control group improved by at least 30% or the ratio of subjects in the test group to the placebo groupPlacebo group According to the statistical method, there is a statistical difference in the total score of SCORAD improvement, at least reaching one of the two items. |
Contacts
Primary ContactSean Lin
Backup ContactNina Chen
Outcome results
None listed